Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: Data from LUMINA (LXXVI), a multi-ethnic us cohort

Rohan Willis, Alan M. Seif, Gerald McGwin, Laura Aline Martinez-Martinez, Emilio Gonzalez, Ellis Doan, Neha Dang, Elizabeth Papalardo, Jigna Liu, Luis M. Vilá, John D. Reveille, Graciela S. Alarcón, Silvia S. Pierangeli

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: We sought to determine the effect of statin therapy on the levels of proinflammatory /prothrombotic markers and disease activity scores in patients with SLE in a multi-ethnic, multi-centre cohort (LUMINA). Methods: Plasma/serum samples from SLE patients placed on statins (n=21) therapy taken before and after at least 6 months of treatment were tested. Disease activity was assessed using SLAM-R scores. Interleukin (IL)-1β, IL-6, IL-8, tumour necrosis factor (TNF)-a, vascular endothelial growth factor (VEGF) and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Soluble intercellular cell adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and anticardiolipin (aCL) antibodies were evaluated using ELISA assays while high sensitivity C-reactive protein (hsCRP) was assessed by nephelometry. Plasma/serum samples from frequency-matched healthy donors were used as controls. Results: Levels of IL-6, VEGF, sCD40L and TNF-a were significantly elevated in SLE patients versus controls. Statin therapy resulted in a significant decrease in SLAM-R scores (p=0.0199) but no significant changes in biomarker levels were observed. There was no significant association of biomarkers with SLAM-R scores. Conclusion: Statin therapy resulted in significant clinical improvement in SLE patients, underscoring the use of statins in the treatment of SLE.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalClinical and Experimental Rheumatology
Volume32
Issue number2
StatePublished - 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Biomarkers
CD40 Ligand
Vascular Endothelial Growth Factor A
Interleukin-6
Therapeutics
Tumor Necrosis Factor-alpha
Nephelometry and Turbidimetry
Anticardiolipin Antibodies
Vascular Cell Adhesion Molecule-1
Cell Adhesion Molecules
Intercellular Adhesion Molecule-1
Serum
Interleukin-8
Interleukin-1
Immunoassay
C-Reactive Protein
Enzyme-Linked Immunosorbent Assay
Tissue Donors

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients : Data from LUMINA (LXXVI), a multi-ethnic us cohort. / Willis, Rohan; Seif, Alan M.; McGwin, Gerald; Martinez-Martinez, Laura Aline; Gonzalez, Emilio; Doan, Ellis; Dang, Neha; Papalardo, Elizabeth; Liu, Jigna; Vilá, Luis M.; Reveille, John D.; Alarcón, Graciela S.; Pierangeli, Silvia S.

In: Clinical and Experimental Rheumatology, Vol. 32, No. 2, 2014, p. 162-167.

Research output: Contribution to journalArticle

Willis, R, Seif, AM, McGwin, G, Martinez-Martinez, LA, Gonzalez, E, Doan, E, Dang, N, Papalardo, E, Liu, J, Vilá, LM, Reveille, JD, Alarcón, GS & Pierangeli, SS 2014, 'Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: Data from LUMINA (LXXVI), a multi-ethnic us cohort', Clinical and Experimental Rheumatology, vol. 32, no. 2, pp. 162-167.
Willis, Rohan ; Seif, Alan M. ; McGwin, Gerald ; Martinez-Martinez, Laura Aline ; Gonzalez, Emilio ; Doan, Ellis ; Dang, Neha ; Papalardo, Elizabeth ; Liu, Jigna ; Vilá, Luis M. ; Reveille, John D. ; Alarcón, Graciela S. ; Pierangeli, Silvia S. / Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients : Data from LUMINA (LXXVI), a multi-ethnic us cohort. In: Clinical and Experimental Rheumatology. 2014 ; Vol. 32, No. 2. pp. 162-167.
@article{dae8f061b88d416fa1ffd1603b680093,
title = "Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients: Data from LUMINA (LXXVI), a multi-ethnic us cohort",
abstract = "Objective: We sought to determine the effect of statin therapy on the levels of proinflammatory /prothrombotic markers and disease activity scores in patients with SLE in a multi-ethnic, multi-centre cohort (LUMINA). Methods: Plasma/serum samples from SLE patients placed on statins (n=21) therapy taken before and after at least 6 months of treatment were tested. Disease activity was assessed using SLAM-R scores. Interleukin (IL)-1β, IL-6, IL-8, tumour necrosis factor (TNF)-a, vascular endothelial growth factor (VEGF) and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Soluble intercellular cell adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and anticardiolipin (aCL) antibodies were evaluated using ELISA assays while high sensitivity C-reactive protein (hsCRP) was assessed by nephelometry. Plasma/serum samples from frequency-matched healthy donors were used as controls. Results: Levels of IL-6, VEGF, sCD40L and TNF-a were significantly elevated in SLE patients versus controls. Statin therapy resulted in a significant decrease in SLAM-R scores (p=0.0199) but no significant changes in biomarker levels were observed. There was no significant association of biomarkers with SLAM-R scores. Conclusion: Statin therapy resulted in significant clinical improvement in SLE patients, underscoring the use of statins in the treatment of SLE.",
author = "Rohan Willis and Seif, {Alan M.} and Gerald McGwin and Martinez-Martinez, {Laura Aline} and Emilio Gonzalez and Ellis Doan and Neha Dang and Elizabeth Papalardo and Jigna Liu and Vil{\'a}, {Luis M.} and Reveille, {John D.} and Alarc{\'o}n, {Graciela S.} and Pierangeli, {Silvia S.}",
year = "2014",
language = "English (US)",
volume = "32",
pages = "162--167",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2",

}

TY - JOUR

T1 - Effects of statins on proinflammatory/prothrombotic biomarkers and on disease activity scores in SLE patients

T2 - Data from LUMINA (LXXVI), a multi-ethnic us cohort

AU - Willis, Rohan

AU - Seif, Alan M.

AU - McGwin, Gerald

AU - Martinez-Martinez, Laura Aline

AU - Gonzalez, Emilio

AU - Doan, Ellis

AU - Dang, Neha

AU - Papalardo, Elizabeth

AU - Liu, Jigna

AU - Vilá, Luis M.

AU - Reveille, John D.

AU - Alarcón, Graciela S.

AU - Pierangeli, Silvia S.

PY - 2014

Y1 - 2014

N2 - Objective: We sought to determine the effect of statin therapy on the levels of proinflammatory /prothrombotic markers and disease activity scores in patients with SLE in a multi-ethnic, multi-centre cohort (LUMINA). Methods: Plasma/serum samples from SLE patients placed on statins (n=21) therapy taken before and after at least 6 months of treatment were tested. Disease activity was assessed using SLAM-R scores. Interleukin (IL)-1β, IL-6, IL-8, tumour necrosis factor (TNF)-a, vascular endothelial growth factor (VEGF) and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Soluble intercellular cell adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and anticardiolipin (aCL) antibodies were evaluated using ELISA assays while high sensitivity C-reactive protein (hsCRP) was assessed by nephelometry. Plasma/serum samples from frequency-matched healthy donors were used as controls. Results: Levels of IL-6, VEGF, sCD40L and TNF-a were significantly elevated in SLE patients versus controls. Statin therapy resulted in a significant decrease in SLAM-R scores (p=0.0199) but no significant changes in biomarker levels were observed. There was no significant association of biomarkers with SLAM-R scores. Conclusion: Statin therapy resulted in significant clinical improvement in SLE patients, underscoring the use of statins in the treatment of SLE.

AB - Objective: We sought to determine the effect of statin therapy on the levels of proinflammatory /prothrombotic markers and disease activity scores in patients with SLE in a multi-ethnic, multi-centre cohort (LUMINA). Methods: Plasma/serum samples from SLE patients placed on statins (n=21) therapy taken before and after at least 6 months of treatment were tested. Disease activity was assessed using SLAM-R scores. Interleukin (IL)-1β, IL-6, IL-8, tumour necrosis factor (TNF)-a, vascular endothelial growth factor (VEGF) and soluble CD40 ligand (sCD40L) levels were determined by a multiplex immunoassay. Soluble intercellular cell adhesion molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-1 and anticardiolipin (aCL) antibodies were evaluated using ELISA assays while high sensitivity C-reactive protein (hsCRP) was assessed by nephelometry. Plasma/serum samples from frequency-matched healthy donors were used as controls. Results: Levels of IL-6, VEGF, sCD40L and TNF-a were significantly elevated in SLE patients versus controls. Statin therapy resulted in a significant decrease in SLAM-R scores (p=0.0199) but no significant changes in biomarker levels were observed. There was no significant association of biomarkers with SLAM-R scores. Conclusion: Statin therapy resulted in significant clinical improvement in SLE patients, underscoring the use of statins in the treatment of SLE.

UR - http://www.scopus.com/inward/record.url?scp=84904397645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904397645&partnerID=8YFLogxK

M3 - Article

C2 - 24480124

AN - SCOPUS:84904397645

VL - 32

SP - 162

EP - 167

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -